Tags

Type your tag names separated by a space and hit enter

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.
N Engl J Med 2006; 355(14):1409-12NEJM

Authors+Show Affiliations

rsteinbrook@attglobal.net

Pub Type(s)

Comment
Journal Article

Language

eng

PubMed ID

17021315

Citation

Steinbrook, Robert. "The Price of Sight--ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration." The New England Journal of Medicine, vol. 355, no. 14, 2006, pp. 1409-12.
Steinbrook R. The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355(14):1409-12.
Steinbrook, R. (2006). The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. The New England Journal of Medicine, 355(14), pp. 1409-12.
Steinbrook R. The Price of Sight--ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration. N Engl J Med. 2006 Oct 5;355(14):1409-12. PubMed PMID: 17021315.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. A1 - Steinbrook,Robert, PY - 2006/10/6/pubmed PY - 2006/10/19/medline PY - 2006/10/6/entrez SP - 1409 EP - 12 JF - The New England journal of medicine JO - N. Engl. J. Med. VL - 355 IS - 14 SN - 1533-4406 UR - https://www.unboundmedicine.com/medline/citation/17021315/The_price_of_sight__ranibizumab_bevacizumab_and_the_treatment_of_macular_degeneration_ L2 - http://www.nejm.org/doi/full/10.1056/NEJMp068185?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -